TFF PHARMACEUTICALS, INC. (TFFP) News
Filter TFFP News Items
TFFP News Results
|Loading, please wait...|
TFFP News Highlights
- For TFFP, its 30 day story count is now at 2.
- Over the past 22 days, the trend for TFFP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about TFFP are IPA.
Latest TFFP News From Around the Web
Below are the latest news stories about TFF Pharmaceuticals Inc that investors may wish to consider to help them evaluate TFFP as an investment opportunity.
We feel now is a pretty good time to analyse TFF Pharmaceuticals, Inc.'s ( NASDAQ:TFFP ) business as it appears the...
TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients
Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma Pharmacokinetic Data Revealed No Differences in Patients Using Bronchodilators Compared to Healthy Subjects; Allows for Inclusion of Broader Patient Populations in Upcoming Phase 2 Studies Company Expects to Generate Phase 2 Data in IPA in 2022; Data Suggest Potential Utility in Treating Allergic
AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will host a science day related to two of the company’s lead assets, inhaled voriconazole for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021 from 1:30p
Zacks Investment Research downgraded shares of TFF Pharmaceuticals (NASDAQ:TFFP) from a hold rating to a sell rating in a research report report published on Friday, Zacks.com reports. According to Zacks, TFF Pharmaceuticals Inc. is an early-stage biopharmaceutical company. It is focused on the development and commercialization of inhalation products for the treatment of chronic respiratory 
With me on the line today is Glenn Mattes, president and CEO of TFF and Kirk Coleman, chief financial officer; Dr. Dale Christensen, TFF director of clinical development; and Dr. The press release announcing our third quarter results is available on the TFF Pharmaceuticals website.
Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs; Both Programs Advancing into Phase 2 Testing
No summary available.
TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -142.86% and -97.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will present a corporate overview at the 12 th Annual Jefferies London Healthcare Conference taking place November 16-19, 2021.
No summary available.